Literature DB >> 6274962

Abnormal anti-Epstein Barr virus antibodies in carriers of the X-linked lymphoproliferative syndrome and in females at risk.

K Sakamoto, J K Seeley, T Lindsten, J Sexton, J Yetz, M Ballow, D T Purtilo.   

Abstract

The asymptomatic hemizygous female carriers of the X-linked lymphoproliferative syndrome (XLP) have abnormal antibody responses to EBV. This suggests partial expression of the defect that leads to EBV-provoked life-threatening diseases in their affected sons. EBV specific antibodies were measured in 65 serum samples of 12 obligate carrier females and seven of their daughters (females at risk) during periods ranging from 1 to 5 yr. Abnormal qualitative antiviral capsid antigen (VCA) IgG titers were nearly fourfold higher than normal controls, two carriers had persistent IgM anti-VCA antibody, two-thirds had persistent IgA anti-VCA antibody, and half of the women had titers to early antigen (EA). Five of seven females exhibited a similar persistent pattern. In contrast, none of the unaffected family members nor 23 normal controls expressed IgA or IgM titers to VCA even with high exposure to the virus, and anti-EA was detected in only one control. Therefore, these findings may prove useful for detecting carriers of the syndrome. Abnormal anti-EBV titers similar to the carrier pattern have been reported in patients and other immunosuppressed individuals, and are indicative of active viral infection.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6274962

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Prenatal diagnosis and carrier detection in primary immunodeficiency disorders.

Authors:  Y L Lau; R J Levinsky
Journal:  Arch Dis Child       Date:  1988-07       Impact factor: 3.791

2.  Epstein-Barr virus specific antibodies in patients with coeliac disease.

Authors:  S Harada; J Greally; J Davis; N Synder; F Stevens; C McCarthy; D T Purtilo
Journal:  Ir J Med Sci       Date:  1985-11       Impact factor: 1.568

3.  A family study of the X-linked lymphoproliferative syndrome: evidence for a B cell defect contributing to the immunodeficiency.

Authors:  I Ando; G Morgan; R J Levinsky; D H Crawford
Journal:  Clin Exp Immunol       Date:  1986-02       Impact factor: 4.330

Review 4.  X-linked lymphoproliferative disease: genetic lesions and clinical consequences.

Authors:  Andrew J MacGinnitie; Raif Geha
Journal:  Curr Allergy Asthma Rep       Date:  2002-09       Impact factor: 4.806

5.  Mapping the X-linked lymphoproliferative syndrome.

Authors:  J C Skare; A Milunsky; K S Byron; J L Sullivan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

6.  Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP.

Authors:  Umaimainthan Palendira; Carol Low; Anna Chan; Andrew D Hislop; Edwin Ho; Tri Giang Phan; Elissa Deenick; Matthew C Cook; D Sean Riminton; Sharon Choo; Richard Loh; Frank Alvaro; Claire Booth; H Bobby Gaspar; Alessandro Moretta; Rajiv Khanna; Alan B Rickinson; Stuart G Tangye
Journal:  PLoS Biol       Date:  2011-11-01       Impact factor: 8.029

7.  Immune subtyping for pancreatic cancer with implication in clinical outcomes and improving immunotherapy.

Authors:  Jingkai Liu; Qiaofei Liu; Xiang Zhang; Ming Cui; Tong Li; Yalu Zhang; Quan Liao
Journal:  Cancer Cell Int       Date:  2021-02-26       Impact factor: 5.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.